Citizens raised the firm’s price target on DBV Technologies (DBVT) to $55 from $47 and keeps an Outperform rating on the shares. DBV Technologies is advancing toward commercialization of Viaskin Peanut with a strong focus on regulatory filings, and its convenient daily patch, favorable safety profile, and differentiated mechanism support expectations for broad adoption, significant market share in young children, and peak U.S. sales around $3B, making the current valuation appear attractive relative to recent comparable biotech acquisitions, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DBVT:
- DBV Technologies reports Q1 EPS (11c), consensus (12c)
- DBV Technologies: Differentiated Viaskin Peanut Profile and Solid Cash Runway Support Buy Rating
- DBV Technologies price target lowered to EUR 1.01 from EUR 1.37 at Goldman Sachs
- DBV Technologies price target raised to $47 from $45 at Citizens
- DBV Technologies S.A. – American Depositary Shares (DBVT) Q4 Earnings Cheat Sheet